Patents Assigned to Universitat de Barcelona
-
Publication number: 20150132297Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: ApplicationFiled: November 13, 2014Publication date: May 14, 2015Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary and Westfield College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WuerzburgInventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Publication number: 20150099776Abstract: The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 is a (C1-C2) alkyl radical; R2 and R3 are radicals independently selected from the group consisting of F, Cl and methyl R4 is H or OH; A is a birradical selected from the group consisting of —(CH2)n— and —(CH2)-phenyl-(CH2)—; t is an integer from 0 to 1; and n is an integer from 8 to 15, are useful for the treatment of Alzheimer's disease.Type: ApplicationFiled: May 9, 2013Publication date: April 9, 2015Applicants: PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE, UNIVERSITAT DE BARCELONAInventors: Diego Muñoz-Torrero López-Ibarra, Nibaldo Manuel Inestrosa Cantín, Elisabet Viayna Gaza, Irene Sola Lao, Santiago Vázquez Cruz
-
Patent number: 8822698Abstract: Novel amino acids derivatives, in particular some amino acid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.Type: GrantFiled: November 28, 2012Date of Patent: September 2, 2014Assignees: Universite d'Aix-Marseille, Universite de Lorraine, Oreste Piccolo Studio di Consulenza Scientifica, Universitat de Barcelona, Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Flavio Maina, Rosanna Dono, Oreste Piccolo, Daniele Passarella, Francesco Colombo, Joan Bosch, Bernard Maigret, Vincent Leroux
-
Patent number: 8816062Abstract: The compounds of formula (I) substantially in exo form or salts thereof, wherein: X is a biradical selected from —(CH2)n—*, —(CH2CH2O)nCH2CH2—*, methylcyclohexyl and methylphenyl; n is an integer ranging between 1 and 30; Y is a radical selected from —COOH, a substituted phosphoramidite radical and N-hydroxysuccinimide ester (or other active ester) of carboxylic acid; and * represents the place through which X binds to Y, are useful in a general process for solid-phase preparation of maleimide-oligonucleotide derivatives.Type: GrantFiled: May 2, 2011Date of Patent: August 26, 2014Assignee: Universitat de BarcelonaInventors: Ana María Grandas Sagarra, Albert Sánchez González, Enrique Pedroso Muller
-
Publication number: 20140215644Abstract: The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections.Type: ApplicationFiled: May 29, 2012Publication date: July 31, 2014Applicants: FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA, UNIVERSITAT DE BARCELONA, HOSPITAL CLINIC I PROVINCIAL DE BARCELONAInventors: Francisco Lozano Soto, Vanessa Gabriela Martinez, Rafael Fenutria Aumesquet
-
Publication number: 20140180994Abstract: A method for automated decision making includes using situated agents with real time reactivity skills for making decisions according to their individual perceptions and motivations, and further includes integrating into the situated agents one or more pre-established plans by using a model representing sequences of causally related events for supporting the decision making to fulfil coordinately the one or more pre-established plans.Type: ApplicationFiled: July 6, 2012Publication date: June 26, 2014Applicants: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA), UNIVERSITAT DE BARCELONAInventors: Joan Llobera, Melvyn Slater
-
Patent number: 8680126Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO—(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.Type: GrantFiled: August 29, 2011Date of Patent: March 25, 2014Assignees: Universitat de Barcelona, Fundacio Privada Institut d'Inbestigacio Biomedica de Bell Vitge, Fundacio Privada Institute de Recerca Biomedica de Barcelona, Fundacio Privada Parc Cientific de BarcelonaInventors: Joan Gil Santano, Rodolfo Lavilla Grifols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Ma González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
-
Publication number: 20130240728Abstract: A method and system are disclosed for improving characteristic peak signals in electron energy loss spectroscopy (EELS) and energy dispersive x-ray spectroscopy (EDS) measurements of crystalline materials. A beam scanning protocol is applied which varies the inclination, azimuthal angle, or a combination thereof of the incident beam while spectroscopic data is acquired. The method and system may be applied to compositional mapping.Type: ApplicationFiled: November 19, 2012Publication date: September 19, 2013Applicants: Universitat de Barcelona, AppFive LLC, Nanomegas SPRLInventors: Sonia Estrade Albiol, Joaquin Portillo Serra, Francisca Peiro Martinez, José Manuel Rebled Corsellas, Lluis Yedra Cardona, Stavros Nicolopoulos, Steven Kim, Jon Karl Weiss
-
Publication number: 20130190367Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO-(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.Type: ApplicationFiled: August 29, 2011Publication date: July 25, 2013Applicants: UNIVERSITAT DE BARCELONA, FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA DE BARCELONA, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE, FUNDACIO PRIVADA PARC CIENTÍFIC DE BARCELONAInventors: Joan Gil Santano, Rodolfo Lavilla Grífols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Mª González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
-
Publication number: 20130158248Abstract: The compounds of formula (I) substantially in exo form or salts thereof, wherein: X is a biradical selected from —(CH2)n—*, —(CH2CH2O)nCH2CH2—*, methylcyclohexyl and methylphenyl; n is an integer ranging between 1 and 30; Y is a radical selected from —COOH, a substituted phosphoramidite radical and N-hydroxysuccinimide ester (or other active ester) of carboxylic acid; and * represents the place through which X binds to Y, are useful in a general process for solid-phase preparation of maleimide-oligonucleotide derivatives.Type: ApplicationFiled: May 2, 2011Publication date: June 20, 2013Applicant: UNIVERSITAT DE BARCELONAInventors: Ana María Grandas Sagarra, Albert Sánchez González, Enrique Pedroso Muller
-
Publication number: 20130085143Abstract: Novel amino acids derivatives, in particular some amino acid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.Type: ApplicationFiled: November 28, 2012Publication date: April 4, 2013Applicants: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITAT DE BARCELONA, ORESTE PICCOLO STUDIO DI CONSULENZA SCIENTIFICAInventors: Universite D'aix-Marseille, Universite De Lorraine, Oreste Piccolo Studio Di Consulenza Scientifica, Universitat De Barcelona, Centre National De La Recherche Scientifique (C.
-
Patent number: 8404633Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.Type: GrantFiled: June 19, 2009Date of Patent: March 26, 2013Assignees: Hospital Clinic I Provincial de Barcelona, Universitat de Barcelona, Fundacio Clinic per a la Recerca BiomedicaInventors: Francisco Lozano Soto, Jorge Vera Fernandez
-
Publication number: 20120225793Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Applicants: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on Behalf of the University of Arizona, Universitat De Barcelona, Queen Mary and Westfield College, University of London, Hospital Clinic, Julius-Maximilians-University of Wuerzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HE, Fundacio ClinicInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa Rimsza, Thomas Miller, Thomas Grogan, Elias Campo, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emili Montserrat, Victor Moreno, Andreas Zetti, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
-
Patent number: 8131475Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: GrantFiled: July 25, 2006Date of Patent: March 6, 2012Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents of Behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic, Julius-Maximilians-University of Wuerzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of LondonInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa Rimsza, Thomas Miller, Thomas Grogan, Elias Campo, Silvia M Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emili Montserrat, Victor Moreno, Andreas Zettl, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend Smeland, Stein Kvaløy, Harald Holte, Jan Delabie, T. Andrew Lister
-
Publication number: 20110295062Abstract: Equipment for infrared vision of anatomical structures applicable to assist the physicians in endoscopic, fetoscopic or laparoscopic operations and methods for signal processing to enhance said vision, comprising two units that work together: a multimodal or multispectral imaging unit, constituted by a device comprising an endoscope or fetoscope or laparoscope, and additional optical systems to acquire multimodal images of the interior of the patient's body; and an image processing unit, to which said images are transferred, comprising processing devices with a navigation interface which process said images and display the patient's enhanced anatomical map image and the endoscope location, equipped with hardware and software that apply at least five different vision-enhancing methods, namely normalization, segmentation, tracking, mapping and fusion.Type: ApplicationFiled: December 10, 2009Publication date: December 1, 2011Applicants: Fundacio Clinic Per A La Recerca Biomedica Fcrb, Universitat De Barcelona, Hospital Clinic I Provincial De BarcelonaInventors: Eduard Gratacós Solsona, Iván Amat Roldán
-
Publication number: 20110195894Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.Type: ApplicationFiled: June 19, 2009Publication date: August 11, 2011Applicants: HOSPITAL CLINIC I PROVINCIAL DE BARCELONA, FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA, UNIVERSITAT DE BARCELONAInventors: Francisco Lozano Soto, Jorge Vera Fernandez
-
Publication number: 20110195064Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.Type: ApplicationFiled: June 5, 2009Publication date: August 11, 2011Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Bloard of Regents on behalf of the University of Arizona, Queen Mary and Westfiled College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Mazimilians-University of WuerzburgInventors: Lisa Rimsza, Andrew T. Lister, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott